Prescription drug · ANDA
Nelarabine NDC 70771-1685
Nelarabine 5 mg/mL · Injection · Intravenous · Zydus Lifesciences Limited
NDC codes
FDA NDC Directory| Package NDC | 11-digit (billing) | Package | Copy |
|---|---|---|---|
| 70771-1685-1 | 7077116850170771168501 | 1 VIAL in 1 CARTON (70771-1685-1) / 50 mL in 1 VIALMarketed from Nov 17, 2021 | |
| 70771-1685-8 | 7077116850870771168508 | 6 VIAL in 1 CARTON (70771-1685-8) / 50 mL in 1 VIALMarketed from Nov 17, 2021 |
How the 11-digit form is made: The package segment has 1 digit, so one leading zero is added to it (5-4-1 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules
Product information
- Brand name (proprietary)
- Nelarabine
- Generic name (nonproprietary)
- nelarabine
- Active ingredients
- Nelarabine — 5 mg/mL
- Dosage form
- Injection
- Route
- Intravenous
- Labeler
- Zydus Lifesciences LimitedNDC labeler code 70771
- Product type
- Prescription drug
- Marketing category
- ANDA — Abbreviated New Drug Application (generic)Application ANDA 215037
- Marketing start
- Listing expires
- Other FDA classes
- Nucleic Acid Synthesis Inhibitors (Mechanism)
- Identifiers
- Product ID 70771-1685_d96809f2-f942-4f6d-92b9-0a23ec84226dSPL ID d96809f2-f942-4f6d-92b9-0a23ec84226dSPL set ID 877b69a0-0899-455d-926e-f5a7478c31f8RxCUI 603566UNII 60158CV180
- Pharmacologic class
- Nucleoside Metabolic Inhibitor
Billing references
What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.
- HCPCS codeNo match
No drug-specific HCPCS code in Med-Code's directory for this product. The directory is curated and not complete — check the current CMS HCPCS file before billing.
- Administration
Drug administration (CPT 96360–96549)
When a clinician administers the drug, the administration is reported separately. Codes in this range cover hydration, therapeutic injections and infusions, and chemotherapy or other complex drug administration. The right code depends on route, duration and drug type, and self-administered drugs are not billed this way.
- NDC on a medical claim
N470771168501followed by a unit qualifier and the quantityPackage 70771-1685-01. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier
Product label
Current FDA label (SPL), effective .
About NDC 70771-1685
- What is NDC 70771-1685?
- 70771-1685 is the product NDC for Nelarabine, Nelarabine 5 mg/mL injection, listed with the FDA by Zydus Lifesciences Limited. It has 2 package NDCs, shown above in 10- and 11-digit form.
- What drug is associated with this NDC?
- Nelarabine.
- What is the active ingredient?
- Nelarabine.
- Who is the labeler?
- Zydus Lifesciences Limited, NDC labeler code 70771. The labeler is the company responsible for the label; it may be the manufacturer, a repackager or a distributor.
- What other NDCs exist for Nelarabine?
- 13 other product NDCs are listed under this name. See all Nelarabine NDCs.
- Is there a related HCPCS / J-code?
- Not in Med-Code's curated HCPCS directory. See Billing references above.
Related NDCs: other Nelarabine products
Other finished products listed under the same name: strengths, forms and labelers.
| Product | Strength | Form · route | Labeler | Product NDC | Package NDCs (11-digit) |
|---|---|---|---|---|---|
| nelarabine | Nelarabine 5 mg/mL | InjectionIntravenous | Shorla Oncology Inc. | 81927-375 | 81927-0375-01 |
| Nelarabine | Nelarabine 5 mg/mL | InjectionIntravenous | XGen Pharmaceuticals DJB, Inc. | 39822-0650 | 39822-0650-0139822-0650-06 |
| Nelarabine | Nelarabine 5 mg/mL | InjectionIntravenous | Novadoz Pharmaceuticals LLC | 72205-154 | 72205-0154-0172205-0154-04 |
| Nelarabine | Nelarabine 5 mg/mL | Injection, SolutionIntravenous | Sagent Pharmaceuticals | 25021-259 | 25021-0259-5025021-0259-51 |
| Nelarabine | Nelarabine 5 mg/mL | InjectionIntravenous | Alembic Pharmaceuticals Limited | 46708-813 | 46708-0813-5046708-0813-63 |
| Nelarabine | Nelarabine 5 mg/mL | InjectionIntravenous | Alembic Pharmaceuticals Inc. | 62332-813 | 62332-0813-5062332-0813-63 |
| Nelarabine | Nelarabine 5 mg/mL | InjectionIntravenous | Gland Pharma Limited | 68083-233 | 68083-0233-06 |
| Nelarabine | Nelarabine 5 mg/mL | InjectionIntravenous | Amneal Pharmaceuticals LLC | 70121-1743 | 70121-1743-0170121-1743-04 |
| nelarabine | Nelarabine 5 mg/mL | InjectionIntravenous | Shorla Oncology Inc. | 81927-111 | 81927-0111-0181927-0111-06 |
| Nelarabine | Nelarabine 5 mg/mL | InjectionIntravenous | Meitheal Pharmaceuticals Inc | 71288-165 | 71288-0165-54 |
Other NDCs under ANDA 215037
Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.
| Product | Strength | Form · route | Labeler | Product NDC |
|---|---|---|---|---|
| Nelarabine | Nelarabine 5 mg/mL | InjectionIntravenous | Zydus Pharmaceuticals USA Inc. | 70710-1726 |
| Nelarabine | Nelarabine 5 mg/mL | InjectionIntravenous | Zydus Pharmaceuticals USA Inc. | 70710-1839 |